Decoy Therapeutics Inc (DCOY)

$0.82 +0.05 (6.47%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -5.58M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 300,200
Avg Vol 2,367,350
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 80%
Beta N/A
Analysts Hold
Price Target N/A
Latest News on DCOY
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Jan 7, 2026, 8:45 AM EST - 3 days ago

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dec 19, 2025, 11:12 AM EST - 22 days ago

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Dec 18, 2025, 7:50 AM EST - 23 days ago

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Dec 1, 2025, 8:00 AM EST - 5 weeks ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Nov 19, 2025, 2:42 PM EST - 7 weeks ago

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 2 months ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Nov 11, 2025, 9:18 AM EST - 2 months ago

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Oct 13, 2025, 8:45 AM EDT - 3 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 9, 2025, 8:00 AM EDT - 4 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 5 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Jul 14, 2025, 8:30 AM EDT - 6 months ago

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 9 months ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 10 months ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 1 year ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Jan 13, 2025, 2:12 PM EST - 1 year ago

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 2 years ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 2 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 2 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 19, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022, 8:01 AM EST - 3 years ago

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 13, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Dec 1, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Nov 3, 2022, 9:57 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 27, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 19, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Oct 18, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Oct 14, 2022, 8:43 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Sep 20, 2022, 12:00 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing's Sarcoma and FET-Rearranged Sarcomas

Aug 22, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing's Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Aug 8, 2022, 2:54 PM EDT - 3 years ago

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 8, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update